Zusammenfassung
Auch in diesem Jahr gibt der jährliche Arzneiverordnungsreport (Schwabe U, Paffrath D (Hrsg). Arzneiverordnungsreport 2004. Berlin, Heidelberg: Springer-Verlag, 2004, ISBN 3-540-21359-7) wichtige und spannende Informationen über das Verordnungsverhalten der niedergelassenen Ärzteschaft. Der Report übt im Vergleich zu früheren Ausgaben eine neue, eher nüchtern-wissenschaftliche Zurückhaltung in seinen Interpretationen. Allerdings fallen doch gelegentlich Widersprüche auf, die vermutlich den unterschiedlichen Autorenschaften zuzuschreiben sind.
Literatur
-
1
Auquier P, Robitail S, Llorca PM, Rive B.
Comparison of escitalopram and citalopram efficacy: A meta-analysis.
International Journal of Psychiatry in Clinical Practice.
2003;
7
259-268
-
2
Barbui C, Campomori A, D'Avanzo B, Negri E, Garattini S.
Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates.
Soc Psychiatry Psychiatr Epidemiol.
1999;
34
152-156
-
3
Carlsten A, Waern M, Ekedahl A, Ranstam J.
Antidepressant medication and suicide in Sweden.
Pharmacoepidemiol Drug Saf.
2001;
10
525-530
-
4
Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P.
AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Lancet.
2004;
363
2105-2115
-
5
Davis JM, Chen N, Glick ID.
A meta-analysis of the efficacy of second-generation antipsychotics.
Arch Gen Psychiatry.
2003;
60
553-64
-
6
Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K, Gardner D, Faulding J, Madeley R.
Deliberate self-harm and antidepressant drugs: Investigation of a possible link.
Br J Psychiatry.
2000;
177
551-556
-
7
Fritze J.
Innovative Therapien erfordern zusätzliche finanzielle Ressourcen - Teil III (Antidepressiva).
Neurotransmitter.
2001;
12
33-39
-
8
Fritze J.
Innovative Therapien erfordern zusätzliche finanzielle Ressourcen - Teil I (Antipsychotika).
Neurotransmitter.
2001;
12
40-43
-
9
Fritze J.
Innovative Therapien erfordern zusätzliche finanzielle Ressourcen - Teil II (Antidementiva).
Neurotransmitter.
2001;
12
30-31
-
10
Fritze J, Gastpar M.
Demenzkranke bitte nicht diskriminieren. Stellungnahme zur Kritik am Wirksamkeitsnachweis von Cholinesterasehemmern.
Psychoneuro.
2004;
30
512-513
-
11
Fritze J, Schmauß M.
Off-Label-Use: Der Fall Methylphenidat.
Psychoneuro.
2003;
29
302-304
-
12
Geddes J, Freemantle N, Harrison P, Bebbington P.
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
BMJ.
2000;
321
1371-1376
-
13
Gorman JM, Korotzer A, Su G.
Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials.
CNS Spectrums.
2002;
7
40-44
-
14
Gunnell D, Middleton N, Whitley E. et al. .
Why are suicide rates rising in young men but falling in the elderly? A time-series analysis of trends in England and Wales 1950-1998.
Soc Sci Med.
2003;
57
595-611
-
15
Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P.
Association between antidepressant prescribing and suicide in Australia, 1991-2000: Trend analysis.
Br Med J.
2003;
326
1008-1011
-
16
Healy D.
Lines of evidence on the risks of suizide with selective serotonin reuptake inhibitors.
Psychother Psychosom.
2003;
72
71-79
-
17
Jureidini JN, Doecke Ch, Mansfiedl R, Haby M, Menkes B, Tonkin A.
Efficacy and safety of antidepressants for children and adolescents.
BMJ.
2004;
328
879-883
-
18
Lepola U, Wade A, Andersen HF.
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Int Clin Psychopharmacol.
2004;
19
149-155
-
19
Mann K, Lehert Ph, Morgan MY.
The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis.
Alcohol Clin Exp Res.
2004;
28
51-63
-
20
Olfson M, Shaffer D, Marcus SC.
Relationship between antidepressant medication treatment and suicide in adolescents.
Arch Gen Psychiatry.
2003;
60
978-982
-
21
Rihmer Z.
Can better recognition and treatment of depression reduce suicide rates? A brief review.
Eur Psychiat.
2001;
16
406-409
-
22
Svensson S, Mansfield PR.
Escitalopram: superior to citalopram or a chiral chimera?.
Psychother Psychosom.
2004;
73
10-16
-
23
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine Study Group .
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil.
JAMA.
2004;
291
317-324
Korrespondenzadresse:
Prof. Dr. med. Jürgen Fritze
Asternweg 65
50259 Pulheim
